Spyre 3-pronged IBD strategy on track with IL-23 drug ph. 2 win
Spyre 3-pronged IBD strategy on track with IL-23 drug ph. 2 win
Spyre Therapeutics
SYRE $90.25 USD
Biopharmaceutical company - Antibodies
Company Info
Recent News
Spyre tumbles as immune drug misses mark in rheumatoid arthritis
Spyre tumbles as immune drug misses mark in rheumatoid arthritis
Spyre’s rheumatoid arthritis plan toppled by subpar TL1A data
Spyre’s rheumatoid arthritis plan toppled by subpar TL1A data